Healthcare Claims Data Explained: Medical Claims vs Pharmacy Claims vs All-Payer Databases

What Healthcare Claims Data Is — and Why Commercial Teams Can't Operate Without It

CMS processes more than 1.5 billion Medicare fee-for-service claims annually, according to CMS statistics reports — a structured record of nearly every clinical encounter, prescription dispensed, and procedure performed for America's 65 million Medicare beneficiaries. For pharma and medical device commercial teams, those records represent something more actionable than billing data: an HCP-level account of what physicians are prescribing, which procedures they're performing, and how their clinical behavior is shifting over time.

Healthcare claims data is the administrative record generated whenever a covered healthcare service is delivered. A physician performs a lumbar fusion — a medical claim is filed. A patient fills a prescription for a GLP-1 receptor agonist — a pharmacy claim is generated. An outpatient facility bills for a device implant — another set of coded records enters the system. Each of these records captures structured, standardized information that reveals actual clinical behavior at the individual provider level, backed by payer settlement — something no sales call report, physician survey, or market research proxy can replicate.

This guide explains the three core types of healthcare claims data that commercial teams work with: medical claims (procedure data), pharmacy claims (Rx data), and all-payer databases. Understanding what each type captures, how they differ, and how they're used for targeting is the prerequisite for building any serious pharma or medtech commercial analytics strategy.

What Are Medical Claims? Procedure-Level Data for Pharma and MedTech Teams

Medical claims are filed whenever a clinical procedure, diagnostic service, office visit, or inpatient admission is performed and billed to a payer. CMS processes well over a billion Part A and Part B fee-for-service claims per year — covering the full spectrum of clinical encounters for the Medicare population.

Each medical claim is coded with a standardized set of identifiers that make it analytically useful. ICD-10-CM diagnosis codes classify the patient's condition. CPT and HCPCS procedure codes describe the specific service performed — from an office visit to a spinal cord stimulator implant. The National Provider Identifier (NPI) ties the claim to a specific physician, group practice, or facility. Place-of-service codes indicate the clinical setting, and the claim records the date of service, procedure count, and reimbursement amount.

For medical device commercial teams, this is the most direct targeting signal available. A neuromodulation company launching a new implantable device can use procedure claims to identify every neurosurgeon and pain management physician in a target territory who performed implant procedures in the past 12 months, rank them by volume, and determine whether volume is growing or contracting. That specificity replaces territory management based on rep memory and outdated call lists with data-driven prioritization.

Pharma commercial teams use medical claims differently. Procedure and diagnosis codes reveal the geographic concentration of a condition, the specialist population actively treating it, and the referral pathways between primary care and specialty practice in a given territory. An oncology brand team uses this data to answer the denominator question first: how many oncologists in each region are actively managing the condition their drug treats? Pharmacy claims then answer the prescribing question on top of that foundation.

What Are Pharmacy Claims? Rx-Level Prescribing Data Explained

Pharmacy claims are generated when a prescription is dispensed — at a retail pharmacy, specialty pharmacy, mail-order facility, or in-office dispensary. They capture the specific drug dispensed, the exact formulation and dosage, the prescribing physician, the dispensing pharmacy, and the payer who reimbursed the fill.

Approximately 51 million Medicare beneficiaries were enrolled in Part D prescription drug plans in 2023, according to CMS enrollment data. CMS publishes the Medicare Part D Prescriber Public Use File annually — a physician-level dataset showing the total number of claims, drug costs, and beneficiary counts for every drug each provider prescribed in the Medicare program. This file is the foundational public dataset behind most pharma commercial targeting tools, and it's free to access.

The codes that make pharmacy claims analytically useful for commercial strategy include the NDC (National Drug Code) — an 11-digit identifier for the specific drug product, strength, and packaging form that allows direct differentiation between branded and generic drugs and between competing products in the same therapeutic class. The NPI creates the HCP-level link between a dispensed drug and the clinician who ordered it. DAW (Dispense as Written) codes indicate whether the prescriber required brand dispensing or permitted generic substitution — a signal of prescriber conviction in a specific product. Days supply and quantity fields enable treatment duration and patient adherence analysis.

For pharma field teams, pharmacy claims answer the most direct commercial question: which physicians are actively writing prescriptions in a given therapeutic area, at what volume, and how that volume breaks down by brand versus competitors? A rep launching a new biologic in rheumatology doesn't need to approximate prescribing behavior through specialty directory lists or conference attendance — claims data shows exactly who is writing, how much, and for which products. A healthcare commercial intelligence platform surfaces this data at the HCP level, enriched with verified contact details, affiliations, and Open Payments compliance flags.

Medical Claims vs Pharmacy Claims: What Each Type Tells You

Both claim types provide HCP-level behavioral data, but they answer different commercial questions and apply to different commercial use cases. The table below compares them across the dimensions that matter most for pharma and medtech targeting teams.

The practical implication for most pharma commercial teams: you need both. Medical claims identify the specialist population treating your condition and the geographic concentration of diagnosis volume. Pharmacy claims then identify which of those specialists are active prescribers in your therapeutic class — and what your brand's market share looks like compared to competitors writing to the same patient population. G LNK's claims data capabilities combine both claim types, covering 3B+ Rx claims and 5B+ procedure claims from CMS programs, giving commercial teams a complete picture of clinical activity rather than a partial one.

What Are All-Payer Claims Databases — and When Does Coverage Matter?

CMS claims data is comprehensive for the Medicare and Medicaid populations — approximately 150 million Americans combined. But Medicare predominantly covers patients 65 and older, which means CMS data structurally underrepresents conditions concentrated in commercially insured, younger populations. For therapeutic areas like type 1 diabetes, multiple sclerosis, reproductive endocrinology, or pediatric rare diseases, restricting commercial analysis to CMS data means working with a systematically incomplete picture of the patient and prescriber landscape.

All-Payer Claims Databases (APCDs) address this coverage gap by aggregating claims from all payer types — Medicare, Medicaid, commercial insurance, and in some cases self-pay — within a defined geographic area. According to SHADAC (State Health Access Data Assistance Center), more than 20 states have established mandatory APCDs that require payers operating in those states to submit standardized claims data across all insurance types. These databases enable population-level analyses that CMS data alone cannot support.

The federal equivalent is the AHRQ Healthcare Cost and Utilization Project (HCUP), which maintains the largest collection of longitudinal hospital care data in the United States — covering inpatient stays, ambulatory surgery, and emergency department encounters across 48 states. HCUP is widely used for academic research and market sizing analyses, and it provides a multi-payer view of facility-level care that complements CMS fee-for-service data.

For commercial analytics teams, understanding which sources underlie a claims dataset determines what questions it can reliably answer:

CMS claims are authoritative for Medicare and Medicaid populations and are the foundation of most HCP-level prescribing analysis platforms. The IQVIA Institute's annual Medicine Use in the U.S. report consistently shows that Medicare Part D represents a substantial share of total prescription volume for many therapeutic areas — particularly specialty drugs, cardiovascular medications, and oncology treatments — making CMS data sufficient for a large proportion of pharma commercial analyses.

Commercial payer claims require data partnerships with pharmacy benefit managers (PBMs) or insurance carriers, extend coverage to commercially insured patients under 65, and typically carry more restrictive licensing terms.

APCDs provide geographic completeness for states where they exist but vary in availability, scope, and recency of data.

G LNK's platform is built on CMS claims as its core data foundation. For clients who need full multi-payer coverage extending to commercially insured populations, private claims are available through G LNK's data partner network — a premium add-on for teams that need complete market coverage across all payer types.

How Pharma and MedTech Commercial Teams Use Claims Data

Claims data is most valuable when it moves commercial decisions from intuition-based to evidence-based. The CMS Medicare Part D Prescriber Public Use File answers the three foundational targeting questions — who prescribes what, in what volume, and where — for the Medicare population with a level of specificity that no other publicly available data source matches.

Territory sizing and HCP segmentation. Claims data quantifies the total addressable prescriber population in each territory — ranking individual HCPs by actual Rx or procedure volume rather than specialty directory presence. Two geographically similar territories may have a 3x differential in addressable prescribers once actual volume data is applied. The G LNK guide to building territory plans with claims data details how commercial teams translate raw claims analytics into actionable territory models.

Competitive market share analysis. Comparing prescription volume for your brand's NDC codes against competitor NDC codes within the same prescriber's patient population produces HCP-level market share data. This identifies not just who the high-volume prescribers are, but which are heavily weighted toward a competitor — distinguishing retention risks from acquisition targets.

Launch and adoption tracking. For new drug launches or device introductions, claims data provides a baseline of current treatment patterns, then tracks how adoption spreads week by week. The questions that drive field prioritization during a launch — which high-volume prescribers have not yet written a single prescription, which early adopters are worth investing in — are answerable directly from claims data. How pharma sales reps use claims data, Open Payments, and prescribing analytics walks through how this workflow operates in practice.

Device procedure targeting. MedTech field reps use CPT-coded procedure claims to identify the highest-volume surgeons for a specific intervention. Procedure volume concentration among a small percentage of physicians is a consistent empirical pattern across surgical specialties — and procedure claims are the only reliable way to quantify it at the individual surgeon level.

Evaluating Claims Data Quality Before You Build On It

The FDA's Real-World Evidence program identifies data provenance, completeness, and representativeness as the core quality dimensions for any claims-based analysis — criteria that apply directly to commercial intelligence use cases.

Coverage completeness defines what percentage of total prescribing or procedure volume a dataset actually captures. A dataset built solely on Medicare Part D misses prescribing to commercially insured patients under 65. A dataset from a single PBM misses fills at pharmacies outside that network. Coverage gaps that aren't disclosed can produce systematically misleading market share estimates.

Temporal depth determines what trend analysis is possible. Identifying whether a prescriber's volume is growing, stable, or declining requires multiple years of longitudinal data — a single annual snapshot shows current behavior but not trajectory. Historical depth is particularly important for competitive positioning: a prescriber who has been loyal to a competitor for four years requires a different commercial strategy than one who recently switched.

HCP linkage accuracy determines whether claims records can be reliably matched to identifiable physicians. NPI-level linkage is the standard, but the quality of the match from a raw claim to a complete HCP profile — verified specialty, affiliation, address, and contact information — varies significantly across data products. The NPPES NPI Registry maintained by CMS is the authoritative source for provider identity verification; platforms that enrich claims data with NPPES-validated NPI records provide more reliable HCP matching than those relying on secondary identifier systems.

Research published in Health Affairs has consistently documented that the accuracy of claims-based provider attribution depends heavily on NPI linkage methodology — with errors in specialty attribution or practice affiliation creating material targeting errors for commercial teams working from poorly linked datasets.

From Raw Claims Records to Actionable Commercial Intelligence

Raw CMS claims files — even when publicly available — require substantial normalization, linkage, aggregation, and enrichment before they become usable for commercial decisions. Transforming flat claims data into an HCP-level targeting view involves connecting claim records to complete provider profiles, aggregating at the prescriber and territory level, and enriching with affiliation, contact, compliance, and institutional data.

The CMS Open Payments database adds a further dimension beyond claims: tracking financial transfers between pharmaceutical and device manufacturers and HCPs for compliance and engagement intelligence. Integrating Open Payments with Rx and procedure claims creates a fuller picture of each HCP's prescribing behavior and manufacturer relationship history — data that matters for both targeting prioritization and compliant engagement.

G LNK's platform handles the full data infrastructure — processing CMS procedure and Rx claims alongside 9.2M+ HCP profiles, 68K+ institutional records, and $11B+ in tracked Open Payments data — so commercial teams work with actionable intelligence rather than raw records. To explore how claims analytics, HCP profiles, and compliance data work together in a single workflow, request a demo or start a free Health Explorer trial to see the platform's prescribing and procedure data firsthand.

You Might Also Like

• How Pharma Commercial Teams Use Claims Data and Prescribing Analytics to Build Smarter Territory Plans

• How Pharma Sales Reps Use Claims Data, Prescribing Analytics, and Open Payments to Target the Right Physicians

• What Is Healthcare Commercial Intelligence? The Complete Guide for Pharma and MedTech Teams

• Best HCP Data Providers in 2026: How to Choose the Right Healthcare Provider Database